At Remedium Bio-Technology our medical focus is unwavering as we pursue a commitment to provide the world's medical profession the best clinically researched products to market to assist patients with their conditions globally.
This focus determines where many of our research and development programs start. Over the past twenty years we have seen an unprecedented expansion in the study of human biology, with advances in human genetics, cancer genomics, stem cell biology, bioinformatics and systems biology all paving the way for new therapies. In the future, advances not only in medicinal chemist1Y but in areas such as protein engineering, antibody drug conjugates and immunotherapies will set us new targets into reach.
To ensure this medical expansion continues, Remedium Bio-Technology have established their own in-house IRDT program. This program has the sole purpose of Identifying, Researching, Developing and Testing new medicines for the treatment of numerous conditions and illnesses that have yet to be identified as benefiting from the new medical treatments now available.
We are assisted with our IRDT program by many well-respected medical professionals and clinical collars, all of whom bring their own skill sets to the program and help with exploring some of the technologies and platforms that we are using to discover and develop new and innovative medicines from our medical technology facility.
At Remedium Bio-Technology we are constantly investing in to new research and development to tackle even the most debilitating and widespread cancers.
With Our clinical research and development program in to the use of Cannabinoids for use in medicine is now established and accepted as being 'cutting-edge'.